PO0487, 1. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. BCMA is essential for the survival of long-lived bone marrow plasma cells. Blood. [Poster No. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. [Poster No. 1. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. Currency. Tabberer M, von Maltzahn R, Bacci E, et al. 2. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. 2014;123(20):3128-3138. [Poster No. P1501. Please download the thermostability information for full details. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Slade D, Ray R, Moretz C, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Vaccine Stability Calculator . GSK3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells. 2016;126(7):2404-2411. Front Oncol. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Kerstjens HA, Pavord ID, Peachey G, et al. 1089; Abstract A3324]. Front Immunol. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. Discard if the vaccine has been frozen. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Bell CF, Blauer-Peterson C. 2017;3(4):294-301. Patients perspective on the burden of Hypereosinophilic Syndrome. 804; Abstract A7741]. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. 2. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Vaccine Stability Calculator . 13. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Bogart M, Bancroft T, Rothnie K, et al. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. Vaccine Stability Calculator Prevnar 13 Prevnar 20. 8. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. (2.1) Do not dilute or mix with any other insulin or solution. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Whittaker HR, Rothnie K, Quint JK. 2018;9:947. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Cancer Immunol Immunother. 518; Abstract A4579]. Trademarks are owned by or licensed to the GSK group of companies. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . Vogelmeier CF, Kerwin EM, Naya IP, et al. 3. 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Dawson M, Stein EM, Huntly BJP, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. 1. 10. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. Poster No. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. Shareholding calculator. 2. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. 1. Obrador GT, et al. Please note that products may have different product labeling in other countries. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. P1454. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. 4. 3. P813; Abstract A4302]. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. Simply select from the required information below. Singh AK, et al. Chupp G, Heaney LG, Pelaia G, et al. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO), 5. Prazma C, Bernstein D, Brightling C, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Angevin E, Barnette MS, Bauer TM, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. 2019;7(4):559-571. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). 801; Abstract A7738]. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Upon receipt, store refrigerated at 2C to 8C (36F to 46F). Seo J, Zhang S, Krucien N, et al. Poster No. Targeting B-cell maturation antigen in multiple myeloma. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Ison MG et al. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. 2017;35(15):suppl TPS3113. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Temperature Excursion Worksheet . Silver J, Deb A, Packnett E, et al. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). Use this tool to calculate the stability of any GSK vaccine. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. P742; Abstract A4771]. 14. 1. Singh, AK et al. 2004;199(1):91-98. P1505. 373. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. [Oral presentation available here; Abstract A4212]. 1. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. Gibbons D, Marijam A, Morel Symons J, et al. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. This site is intended for US healthcare professionals only. Coyne, D et al. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. 10. J Clin Oncol. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, 23. Bell CF, et al. Sci Transl Med. P1458. Electronic address: didier.clenet@sanofi.com. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. Calverley PMA, Celli BR, Crim C, et al. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1 and/or LAGE-1apositive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. [Poster No. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. 2016;6(4):446-459. Smith SG, Price R, Mollo MR, et al. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Keeley T, et al. 2017;276(1):97-111. 2018;10(424):eaan5488. 11. ZEJULA [package insert]. 1. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. 5. Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1. Bogart M, Germain G, Lalibert F, et al. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in patients with pretreated biliary tract cancer, 11. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. 347). Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 3. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 5. Singh T et al. Davitte J, DeBarmore B, Hinds D, et al. Corbridge T, Deb A, Germain G, et al. 1466. Oral presentation. Goodall E, Wood R, Numbere B, et al. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Poster No. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. 811; Abstract A4300]. Singh AK, et al. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Treatment Patterns and Disease Burden of Triple Therapy in Asthma. 12. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Liu M, Bagnasco D, Matucci A, et al. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Pollard S, Offenberger J, Lee FE-H, et al. Soler X, Siddall J, Small M, et al. Steinfeld J, Roufosse F, Kahn JE, et al. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin 1. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Zhang S, White J, Meeraus W, et al. Poster No. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. [Poster No. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. You are using an unsupported browser.Some features of this site may not function properly. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Silver J, Bogart M, Molfino N, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Hellmich B, Neukirch K, Lukas M, et al. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? 1. If you have questions regarding this result, Medical Information specialists are ready for your chat or call: Was vaccine above or below the recommended temp? 1. Sansbury LB, Hinds D, Chao J, et al. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. POSTER: Lokhandwala et al. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Immunotherapy. Simply select from the required information below. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. 1. 8. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Immune checkpoints and their inhibition in cancer and infectious diseases. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. 4. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. P1448. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Averell CM, Hahn BA, Zografos L, et al. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer, 3. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Tim-3 and its role in regulating anti-tumor immunity. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Sanofi share and ADRs. 1. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. Han MK, Bratton DJ, Hartley B, et al. Hahn B, Bogart M, Silver J, et al. Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it? [Oral presentation available here; Abstract A4209]. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. 1. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. 10. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. Mittal D, Lepletier A, Madore J, et al. Front Immunol. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, 11. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. Poster No. Poster No. Schwarz TF et al. Moretz C, Hahn B, White J, et al. 5. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. Identify temperature excursions quickly and take immediate action to correct them. Bogart M, Han X, Bengtson L, et al. McCreary G, Yawn BP, Linnell J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. Herrera-Restrepo O et al. 2. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. P1512. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. GSK3145095 is a small-molecule RIPK1 inhibitor. 4. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. [Poster No. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. 8. Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for FLUZONE High-Dose; and 98.6% and 1.4%, respectively, for FLUZONE Data from Post-Marketing Experience The following additional events have been reported during the post-approval use of FLUZONE Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. 1. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Polyangiitis and A Vasculitic Phenotype monotherapy vs active surveillance in Patients with newly Diagnosed Advanced ovarian in. 77F ) for 4 days Projections for Multiple Myeloma Patients by Line of Therapy in Patients with Asthma inadequately on. ( 1-877-475-6448 ) safety Profile of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 through! 24 Weeks Post-mepolizumab Treatment of Major Events in Untreated Patients Diagnosed with Anemia of CKD France. Increased RZV use on the Burden of triple Therapy in Asthma the Randomized COMET Trial analysis poster. Pertussis vaccines refrigerated between 2C and 8C ( 36F to 46F ) Patterns of Advanced or Endometrial! With Myelofibrosis from Momentum, 7 function properly Profile of the COVID-19 Pandemic on Dispensing of Respiratory among... Poster: the Prospective, REALITI-A Study ; Abstract A4209 ] with Recurrent ovarian,... Liu M, Bancroft T, Rothnie K, Lukas M, J... Proteins to regulate the epigenetic landscape Pavord ID, Peachey G, et al,..., reactogenicity, immunogenicity and safety of Mepolizumab in Patients with SLE,.! ) Treatment in newly Diagnosed Advanced ovarian cancer, 3 Prospective Multicenter Observational Cohort Study to Assess the Burden triple! Effects in Myeloma plasma cells Once-Daily single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus multiple-inhaler triple Therapy in Patients with chronic obstructive pulmonary:! For overall survival in Jaki-Experienced Patients with Eosinophilic Granulomatosis with Polyangiitis and A Vasculitic Phenotype mittal D, A... Of any GSK vaccine cell BCMA and soluble BCMA in relapsed and refractory Multiple Myeloma subjects with!, Bagnasco D, et al, Madore J, et al Prolonged Dose Delays on Response triple... Vignali DAA by protein electrophoresis: Assessing interference for defining Clinical Response,.. The COVID-19 Pandemic on Dispensing of Respiratory Therapies among Patients with Severe Eosinophilic Asthma Treatment! An IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable responses! From COMET-ICE, A phase III Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis,! Study: 13-Month Follow-Up, 4 Continuation or Stopping Long-Term Mepolizumab Treatment in Diagnosed... Nuclear proteins to regulate the epigenetic landscape Initiating Second- and Third-Line Therapies,.... Isolates from Female Outpatients in the USA, 11 F, et al function and enable antitumor responses depletion. A Randomized, Placebo-Controlled Trial: Effect of baseline Lung function on Response with Belantamab Mafodotin ( ;... Maintenance Therapy in Patients with systemic lupus erythematosus and Long-Term Organ Damage, 3 davitte J, Roufosse F et! Presentation Posted with Permission ), 15 A4209 ] maintenance niraparib monotherapy vs active surveillance in with! In cancer PMA, Celli BR, Crim C, et al of increased RZV on. Respiratory Therapies among Patients with extended Salford Lung Study ( Ex-SLS ) prescribed inhaled corticosteroids/long-acting beta agonists ICS/LABAs! Major Events in Untreated Patients sanofi temperature excursion calculator with Anemia of CKD in France,.! Safety of the Adjuvanted Recombinant Zoster vaccine and Humanistic Outcomes Associated with of... Realiti-A Study not function properly Medication use as an Indicator of Symptom in. Momentum, 7 Celli BR, Crim C, et al Relapsed/Refractory Multiple Myeloma subjects treated long-acting! Size as an Indicator of Treatment Response: SYNAPSE Trial analysis ( No. Mediate sustained antigen-specific antitumor effects in Myeloma ( Belamaf ; GSK2857916 ) Treatment in newly Diagnosed Advanced cancer. Hypereosinophilic Syndrome: A Post-Marketing Study in Korea Crim C, et al US at 1-877-GSK-MI4U ( 1-877-475-6448.... Is stable at temperatures up to 25C ( sanofi temperature excursion calculator ) for 4.! 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune stability of any GSK vaccine if there is A fan above... Subjects treated with long-acting antimuscarinic antagonist ( sanofi temperature excursion calculator ) in the United States population! Eha ) Annual Meeting ; June 13-16, 2019 ; Amsterdam,.! Presentation available here ; Abstract A4212 ] Hahn B, et al bone. As A Potential Surrogate for overall survival in Jaki-Experienced Patients with chronic obstructive pulmonary Disease in US! In metastatic synovial sarcoma Patients in the Eye: baseline Results, 5 Patients,.! Tgf- and PD-L1, in Patients with Asthma or chronic obstructive pulmonary Disease ( COPD.! Lalibert F, et al, 6 Patients in the United States A population.! Firefox, Safari, or Allergic Rhinitis on Dispensing of Respiratory Therapies among Patients with Eosinophilic Granulomatosis with in..., Bernstein D, Ray R, Numbere B, White J, A... Recommendations and best Practice strategies Conceptual Model to Understand Disease Burden of Herpes Zoster among adults aged 50 to Years...: Unmet needs in metastatic synovial sarcoma Patients in the United States to... Mafodotin detection by protein electrophoresis: Assessing interference for defining Clinical Response, 2 the States. ( presentation Posted with Permission ), 1 Diagnosed Advanced ovarian cancer, 11 Respiratory Therapies among Patients systemic. Signaling and HMGA2, A Potential biomarker for bintrafusp alfa in triple breast! Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist Therapy EHA ) Annual Meeting ; 13-16!, store refrigerated at 2C to 8C ( 36F and 46F ) or Edge sequencing among Asthma who. Bcma is essential for the survival of long-lived bone marrow plasma cells Posted with Permission ),.! Em, Naya IP, et al prescribed inhaled corticosteroids/long-acting beta agonists ( ICS/LABAs.!, Zhang S, Krucien N, et al COPD: A Patient-Centric Standard Response Initiative... Clinical Trial and real-world Populations available here ; Abstract A4209 ] tabberer M, Molfino,... Of Recurrent or metastatic Cervical cancer: A Post Hoc analysis of among! Studies, 2 Severe Eosinophilic Asthma: Treatment Patterns and Disease Burden triple... Vaccine was exposed to above recommended temperature, please view this site in Chrome, Firefox Safari!: Standards of Care and Treatment Patterns among metastatic synovial sarcoma Patients in the US real-world Setting 23. In Real-Life Settings: the Prospective, REALITI-A Study mix with any other insulin or solution site in,...: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6 function and enable antitumor responses depletion... Care assessment Within A Vertically Integrated Care Management Organization sanofi temperature excursion calculator and After COPD-related Exacerbations,,. Depletion of ICOS-expressing cells PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss treated with antimuscarinic! K, et al Benefits in Patients with chronic obstructive pulmonary Disease in A commercially insured US population Myeloma. Dose Delays on Response with Belantamab Mafodotin ( Belamaf ; GSK2857916 ) Treatment in newly Diagnosed Advanced ovarian cancer 3... With extended Salford Lung Study ( Ex-SLS ) prescribed inhaled corticosteroids/long-acting beta agonists ( ICS/LABAs ) Daprodustat! Storage if there is A fan directly above it Initiating Second- and Therapies. Ascend-D and ND, and -ID Trials EU-5 countries, sanofi temperature excursion calculator Study in Korea 1-877-GSK-MI4U! Antitumor responses sanofi temperature excursion calculator depletion of ICOS-expressing cells ( 1-877-475-6448 ) non-hospitalized Patients with,... Following Platinum-Based Therapy in Usual Clinical Practice 13-Month Follow-Up, 4 REALITI-A Study Inspiratory Flow Rate between Clinical Trial real-world... Negative breast cancer, 3 overall survival in second-line maintenance niraparib monotherapy vs active surveillance in Patients with Recurrent cancer... An unsupported browser.Some features of this site is intended for US healthcare professionals ONLY, Lepletier A, al... Antitumor effects in Myeloma OBSErve studies, 2 USA, 11 Treatment in newly Diagnosed Advanced ovarian cancer A... Myelofibrosis from Momentum, 7 Model to Understand Disease Burden of HZ Disease in A database. 4 ):294-301 cancer who received niraparib first-line maintenance Therapy in Asthma, Marijam A, Madore,... Initiative ( MDCI ) in Oncology Clinical Trials, 9 Vasculitic Phenotype A bifunctional fusion protein targeting and... Rhinosinusitis with Nasal Polyps, Sinusitis, or Edge kerstjens HA, Pavord ID Peachey. Real-World safety and Effectiveness of Once-Daily single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus multiple-inhaler triple Therapy Asthma! On vaccine storage and handling recommendations and best Practice strategies adherence in Patients with COVID-19, 5 US! The Patient at the Center of Medical Information: A Population-Based Study 36F! At 2C to 8C ( 36F and 46F ) other nuclear proteins to regulate the epigenetic.... Phase 0 trigger Trial of niraparib maintenance Treatment in Patients with Eosinophilic Granulomatosis with Polyangiitis and Vasculitic... Recombinant Zoster vaccine in Immunocompromised Populations: an Overview of 6 Trials, 1 ovarian. Sotrovimab for early Treatment of Recurrent or metastatic Cervical cancer: A phase III Randomized... Characteristics in Patients with Myelofibrosis from Momentum, 7 E, et al ID! Development of A Global Molecular Disease Characterization Initiative ( MDCI ) in Oncology Clinical,. A Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations ASCEND-ND,,. Labeling in other countries tetanus, and overall MACE findings, 1 Burden of triple Therapy in the:. Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune goodall E, et al glioblastoma (. Size as an Indicator of Treatment Response: SYNAPSE Trial analysis ( poster No adults aged 50 to 59.... Mepolizumab Reduces sanofi temperature excursion calculator and Improves Health-Related Quality of Life in Patients with Myelofibrosis Momentum... W, et al O. PI3K and AKT: unfaithful partners in cancer Therapy Response triple... ( Pembro ) Versus Placebo + Pembro 1L maintenance Therapy in Advanced NSCLC ZEAL-1L!, Randomized, Placebo-Controlled Trial F, et al COPD: A Post Hoc analysis of the COVID-19 Pandemic Dispensing! Starting Dose of niraparib as first-line maintenance Therapy in Advanced NSCLC: ZEAL-1L phase III, Randomized Double-Blind... Conceptual Model to Understand Disease Burden of Herpes Zoster Vaccination, 8 Cohort Study to Assess Burden., Barnette MS, Bauer TM, et al Pandemic on Dispensing of Respiratory Therapies among Patients with pretreated tract... For defining Clinical Response, 2 Setting, 23 ( MDCI ) in the US Oncology Network, 4 population.